Market Highlights

• ProfoundBio secured $112.0 million to advance its antibody-drug conjugate (ADC) development pipeline, targeting specific molecular markers for precise delivery of compounds to cells.
• Biotechnology firm Kineta revealed plans to restructure its operations, resulting in a significant reduction of 64% of its workforce, including CEO Shawn ladonato.
• AstraZeneca has completed its $1.1 billion acquisition of Icosavax, a biotech company originating from the University of Washington's Institute for Protein Design in Seattle, integrating it into AstraZeneca's portfolio.

Read the full report